Back to top
more

Boston Scientific (BSX)

(Delayed Data from NYSE)

$75.92 USD

75.92
3,224,432

+0.42 (0.56%)

Updated Jun 4, 2024 04:00 PM ET

After-Market: $76.14 +0.22 (0.29%) 7:34 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (92 out of 249)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).

HRC or BSX: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

HRC vs. BSX: Which Stock Is the Better Value Option?

Boston Scientific Hits New 52-Week High: What's Driving it?

by Zacks Equity Research

Boston Scientific (BSX) is optimistic about sustaining the growth momentum on recent positive developments.

Boston Scientific's First Single-Use Duodenoscope Gets FDA Nod

by Zacks Equity Research

Boston Scientific's (BSX) EXALT Model D single-use duodenoscope gets clearance from the FDA for use in ERCP procedures.

Boston Scientific's Watchman Implant Study Results Encourage

by Zacks Equity Research

These study results are expected to be a major breakthrough for Boston Scientific's (BSX) Cardiovascular segment.

Boston Scientific (BSX) Up 4.5% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Safety Notice Issued by Boston Scientific (BSX) for AngioJet

by Zacks Equity Research

Boston Scientific (BSX) issues an urgent field safety notice for AngioJet Ultra consoles.

Boston Scientific (BSX) Catches Eye: Stock Jumps 5%

by Zacks Equity Research

Boston Scientific (BSX) saw a big move last session, as its shares jumped 5% on the day, amid huge volumes.

Company News For Oct 24, 2019

by Zacks Equity Research

Companies In The News Are: ALXN,ANTM,TMO,BSX

Boston Scientific (BSX) Beats on Q3 Earnings, Tapers EPS View

by Zacks Equity Research

Boston Scientific (BSX) is making an all-out effort to solidify its core businesses and invest in the new technologies as well as the global markets. This reflects on the sales uptick in Q3.

Boston Scientific (BSX) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Boston Scientific (BSX) delivered earnings and revenue surprises of 2.63% and 2.36%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Medical Products' Earnings Roster for Oct 23: TMO, BSX & More

by Zacks Equity Research

Encouraging growth in the emerging markets despite the ongoing trade tiff is likely to contribute to revenues in the medical products space this earnings season.

Trina Mukherjee headshot

Medical Products Industry Outlook: Prospects Seem Promising

by Trina Mukherjee

Growth prospects look bright for the Zacks Medical Products industry, thanks to AI, Medical Mechatronics and Robotics and rampant M&As.

Can Overall Growth Boost Boston Scientific (BSX) Q3 Earnings?

by Zacks Equity Research

We are once again optimistic about the IC business of Boston Scientific (BSX), which is likely to have aided the company to retain impressive global growth in Q3.

Boston Scientific (BSX) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Boston Scientific (BSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Abbott (ABT) Gets FDA Nod for New Troponin-I Blood Test

by Zacks Equity Research

The regulatory go-ahead for Abbott's (ABT) ARCHITECT STAT High Sensitivity Troponin-I blood test is a major stride forward in its commitment for detecting patients suspected of having a heart attack.

Abiomed's (ABMD) Impella 5.5 With SmartAssist Gets FDA Nod

by Zacks Equity Research

Abiomed's (ABMD) flagship Impella heart pump line is a major growth driver.

Medtronic Upbeat on Drug-Eluting Stents in Patients With DAPT

by Zacks Equity Research

Medtronic's (MDT) DAPT study's robust data outcome is likely to aid as the therapy duration might prove to be a superior treatment option.

PETQ vs. BSX: Which Stock Is the Better Value Option?

by Zacks Equity Research

PETQ vs. BSX: Which Stock Is the Better Value Option?

Boston Scientific (BSX) Upbeat on Results of EVOLVE Study

by Zacks Equity Research

Boston Scientific (BSX) is hopeful about robust data outcome on DAPT study as the therapy duration might prove to be a superior treatment option.

BAX or BSX: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

BAX vs. BSX: Which Stock Is the Better Value Option?

Urmimala Biswas headshot

IoMT Becomes the Buzzword in New Age MedTech Investing

by Urmimala Biswas

Increasing adoption of cloud platforms, phones, phablets, tablets and other smart devices as well as apps is making acceptance of IoMT easier among the masses.

Boston Scientific Closes BTG Buyout, PI Arm to Get a Boost

by Zacks Equity Research

In its effort to accommodate the acquisition of BTG, Boston Scientific (BSX) is offloading its certain non-prior businesses.

Boston Scientific (BSX) Up 1.6% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

BAX vs. BSX: Which Stock Is the Better Value Option?

by Zacks Equity Research

BAX vs. BSX: Which Stock Is the Better Value Option?

Boston Scientific's (BSX) Vercise Gevia DBS Gets FDA Nod

by Zacks Equity Research

Boston Scientific's (BSX) Vercise Gevia DBS system should boost neuromodulation revenues for the company.